Dr. Kim Hong-Yeoul, CEO
Despite breakthroughs in anticancer treatments, cancer still remains an unstoppable force. The years of scrupulous scientific researches have brought in multiple treatments, including anticancer chemotheraphies, targeted therapies, and immunotherapy. Lamentably, these come with their own share of cons or setbacks! The chemical therapies are often a cause of concern, affecting the normal, non-cancerous cells while also opening the doors to side effects like gastrointestinal disorders, bone marrow function deterioration, and more. Besides, targeted therapies and immunotherapy indicate poor response rates, toxicities, limited targets, and resistance to treatments, adding to the pitfalls of cancer remediation. Hence, the need of the hour is an anticancer drug that caters to the unmet needs in the oncology space by reducing the side effects while showcasing the maximum efficacy in curing cancer; a need that is rightly fulfilled by HaimBio.
With the motto of defeating cancer using an innovative and safe technique, HaimBio—a South Korean biopharmaceutical company—is working towards introducing the next generation anticancer treatment that harnesses the energy metabolism of cancer cells. HaimBio is bringing to the table their flagship product, Starvanip®, a metabolic anticancer drug that is the first of its kind in Korea, based on a unique mechanism of action. This therapy emphasizes inhibiting the growth of cancer cells by destroying the cells’ energy metabolism through a method known as cancer energy metabolism therapies (CEMBTs).
HaimBio’s metabolic anticancer drug exerts fewer side effects compared to the existing drugs in the market due to the components and methodology leveraged to develop it. Moreover, it is an oral medication that makes it easy to administer and can be effectively used in combination therapy with the other prominent anticancer drugs, improving the efficacy of the treatment drastically.
We are bringing to table a first-in-class anticancer drug based on ATP shrink that inhibits energy formation within the cancer cells and thereby defeats the disease,” mentions Dr. Kim Hong-Yeoul, CEO of HaimBio
Most importantly, HaimBio’s therapy is much more affordable than expensive immunotherapy or other treatments, which is added advantage for a larger population.
The CEMBTs’ distinct mechanism of action is the key to its enhanced efficiency compared to the previously developed therapies. Normal cells produce ATP from glucose to generate energy throughout the TCA cycle; but the story is different for a cancer cell. These cells use the ALDH (Aldehyde dehydrogenase) enzyme to produce NADH (nicotinamide adenine dinucleotide hydride) that moves into the mitochondria and develops ATP (Adenosine triphosphate). This is the process that HaimBio is aiming to restrict. The method deploys specific inhibitors to shrink the NADH and ATP that are the principal energy source of the cancer cells, consequently weakening and killing the cells. The CEO goes on to mention how they could leverage two commonly used drugs called NYH817G and NYH100P, rearranging the constituents and developing the required anticancer therapy. This combination not only suggests higher efficacy but allows the therapy to be considerably inexpensive. “We are bringing to table a first-in-class anticancer drug based on ATP shrink that inhibits energy formation within the cancer cells and thereby defeats the disease,” mentions Dr. Kim Hong- Yeoul, CEO of HaimBio.
An important aspect, instrumental to HaimBio’s efforts in the oncology space, is the attempt to eliminate the anticancer resistance that several patients develop over specific drugs. This is an incredible offering that HaimBio can bring in the medical arena to save lives. In addition to this, the CEO reflects upon the benefits of NYH817G that helps inhibit the functions of LDH from preventing the formation of lactic acid, which is an important energy source for tumour cells.
Through these efforts, HaimBio has traversed a long journey with its innovative anticancer treatment, setting foot into the first metabolic anticancer drug trial in Korea. Moving ahead, IND-approved Starvanip® is expected to complete its first trial and enter into the next one around mid-2022. In fact, HaimBio has laid out plans to conduct its second phase of trials for rare cancers, including GBM, pancreatic cancer, and gradually cover other cancers such as breast cancer, NSCLC, and ovary cancer. The array of benefits that HaimBio aims to offer holistically addresses the needs in the oncology space and bridles the fatal impact of cancer. Their solutions are attempting to showcase not just a compelling and unique method of killing cancer cells but also look into the affordability and easy administering of the therapy, effectively raising hope among people to defeat this deadly disease.